In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Join Drs Steven Feldman and Robert Kushner as they discuss the role of dermatologists in treating obesity in conjunction with psoriasis.

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Methotrexate is a common treatment option for psoriasis. Newer medications ... These drugs inhibit the production of tumor necrosis factor (TNF), an inflammation-causing substance in the blood.